http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010031835-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e61cfb51fa2b44c437821e74916283f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e8b41a5306ac7f3afa3fa5cb663d8e1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a936cfabeb63979e73abc1c752398be5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95179825a4a78ddca3d74a57e07dc078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e9c20d2eebe4500f1f3f2d034a4e35a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D263-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D263-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-421
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427
filingDate 2009-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51847733350b3c3dbd67980c531474f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db0876646b078e9cefb05a14e8fa5542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_840b770acdb7ff4a2435829c7586196f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2479048eb0d83556a89b1ac8c47d6fa7
publicationDate 2010-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2010031835-A3
titleOfInvention 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
abstract The present invention relates to (R,S) 2-aryl-propionic acids and derivatives, their single cnantiomcr (S) and to pharmaceutical compositions containing them, which arc used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonuclcated neutrophils (PIvTN leukocytes) at inflammation sites. The present invention provides compounds for use in the treatment of transient cerebral ischemia, bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and damages caused by ischemia and reperfusion. (Formula (I)
priorityDate 2008-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03043625-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1481465-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4025528-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0158852-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1123276-B1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1032
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6999928
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6999930
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID413807576
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226603229
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID227566934

Total number of triples: 40.